Researchers are investigating whether the same approach used to prevent infectious diseases could treat addictions to such drugs as nicotine and cocaine.
None is yet on the market, but in late September, the National Institute on Drug Abuse
(NIDA) released a $10 million stimulus grant to Nabi Pharmaceuticals to
help pay for the first Phase III trial a large study designed to
confirm effectiveness and monitor side effects of a smoking-cessation
vaccine. Company spokesman Greg Fries says Nabi, based in Rockville,
Md., expects to begin enrolling patients in the NicVax study by year's
end... Read More